Physician profile
Mitchell P Weikert
NPI 1932198397
$127,000.34
in general payments reported to CMS, 2019-2025
18 companies · $30K in 2025
The $30K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $22K · 2021: $8,237 · 2022: $9,391 · 2023: $8,677 · 2024: $24K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $51K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Food and Beverage: $3,187 · Travel and Lodging: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $51,033.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Food and Beverage | $3,187.03 |
| Travel and Lodging | $850.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $76,444.49 | 2019-2025 | |
| Alcon Vision LLC | $17,833.34 | 2019-2025 | Clareon, Centurion, Unity |
| Carl Zeiss Meditec, INC. | $17,158.03 | 2019-2025 | Visumax, Forum, Quatera 700 |
| Bausch & Lomb Americas INC. | $7,666.76 | 2023-2025 | Miebo, Xiidra, Stellaris |
| Rxsight INC | $2,599.94 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Johnson & Johnson Surgical Vision, INC. | $1,923.43 | 2019-2024 | Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $897.48 | 2019 | |
| Glaukos Corporation | $547.27 | 2019-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Sun Pharmaceutical Industries INC. | $531.36 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $501.77 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $229.03 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $164.29 | 2022-2025 | Visumax, Veracity Surgical |
| Dompe US, INC. | $159.54 | 2022 | |
| Heidelberg Engineering, INC. | $135.00 | 2025 | Spectralis |
| Kala Pharmaceuticals, INC. | $98.48 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $53.16 | 2019 | |
| Sight Sciences, INC. | $35.00 | 2022 | |
| Eyepoint US, INC. | $21.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Weikert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.